GeoVax tumbles as HHS ends mid-stage COVID vaccine trial
Shares of drug developer GeoVax Labs GOVX.O fall 16% to 89 cents in extended trading
The U.S. Department of Health and Human Services has decided to terminate GeoVax's COVID-19 vaccine project contract — SEC filing
The reason for the termination is stated as "convenience to the government"
GeoVax received a stop-work notice from Advanced Technology International (ATI) directing them to halt all activities related to the project
The project was funded by the Biomedical Advanced Research and Development Authority (BARDA), a division of HHS
The COVID-19 vaccine was in the mid-stage trial
As of last close, stock fell 5.7% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
SpaceX IPO Guide: Can You Buy SpaceX IPO Shares on Robinhood? How Can Investors in Asia and Europe Buy SpaceX IPO Shares?

Anthropic Revenue Surpasses OpenAI for First Time, IPO as Early as October

Chevron Stock Analysis: A Stock Warren Buffett Bet Big On—Should You Invest in 2026 Despite High Oil Prices?

Meta Is About to Launch a Consumer-Facing AI Model, and OpenAI Is About to Have Its IPO, Making Now a Good Time to Buy Meta Stock

IonQ vs. Rigetti Computing: Which Quantum Computing Stock Has the Edge Now?

Tradingkey







